Clinical trials: Androgen Deprivation Therapy
Prostate Adenocarcinoma
Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer
The goal of this clinical trial is to study definitive external beam radiation therapy together with drugs called androgen deprivation therapy (ADT) in patients with prostate cancer.
- Trial name
- SENTRY (NCT07364071)
- Testing
- Radiation therapy
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of California, San Diego
Prostate Cancer, Sarcopenia
Creatine Supplementation and Resistance Training to Improve Sarcopenia Parameters in Patients With Prostate Cancer After Androgen Deprivation Therapy
This randomized, double-blind, placebo-controlled clinical trial will investigate the effects of creatine supplementation combined with a 12-week supervised resistance training program on muscle mass, muscle strength, physical…
- Trial name
- NCT07463092
- Testing
- Creatine Monohydrate, Maltodextrin, Resistance training
- Where
- Brazil
- Volunteers
- 34 people
- Sponsor
- University of Sao Paulo
Prostate Cancer
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC).
- Trial name
- NCT04631744
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Weill Medical College of Cornell University
Salivary Gland Neoplasm Duct
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma
The purpose of the study is to evaluate the efficacy and safety of rezvilutamide in combination with androgen deprivation therapy (ADT) in participants with androgen receptor (AR) positive, high-risk salivary duct carcinoma…
- Trial name
- NCT06348264
- Testing
- Rezvilutamide, Leuprolide Acetate
- Where
- 2 sites in China
- Volunteers
- 37 people
- Sponsor
- Peking University First Hospital
Sarcopenia, Prostate Cancer
Changes in Body Composition With Patients Under Androgen Deprivation Therapy
This study aimed to evaluate the correlation of change in body composition and oncological outcomes of prostate cancer patients under androgen deprivation therapy(ADT).
- Trial name
- NCT04037488
- Testing
- Inbody 320
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Seoul National University Hospital
Prostate Cancer, Malignant Neoplasm of Prostate
MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
The purpose of this study is to find out if giving radiation therapy (RT) to areas of metastatic prostate cancer at the time a participant is diagnosed will help control disease better than the usual treatment.
- Conditions
- Prostate Cancer, Malignant Neoplasm of Prostate, Secondary Malignant Neoplasm of Prostate
- Trial name
- NCT06150417
- Testing
- Androgen deprivation therapy (ADT), Androgen receptor signaling inhibitor (ARSI), Local Therapy: Radical Prostatectomy (RP) or Radiotherapy (RT)
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Carcinoma, Recurrent Prostate Carcinoma
Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial
This phase II trial compares the effect of time-restricted eating (TRE) and glucagon-like peptide-1 (GLP1) receptor agonists (RA), semaglutide and tirzepatide, to an American Heart Association (AHA) heart healthy diet (HHD)…
- Trial name
- NCT07202247
- Testing
- Antiandrogen Therapy, Behavioral Intervention, Biospecimen Collection
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- City of Hope Medical Center
Sarcopenia, Prostate Cancer
Identifying Fundamental Mechanisms of Skeletal Muscle Ageing in Older Men Undergoing Androgen Deprivation Therapy: a Feasibility Study
To find out whether it is possible to run a study looking at the underlying markers of ageing in muscle quality and quantity in men receiving Androgen Deprivation Therapy for prostate cancer treatment.
- Conditions
- Sarcopenia, Prostate Cancer, Muscle Atrophy, Androgen Deprivation Therapy
- Trial name
- MASS-ADT (NCT07134439)
- Volunteers
- 20 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Prostate Cancer
Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
RATIONALE: Radiation therapy (RT) uses high-energy x-rays to damage tumor cells. Androgens can stimulate the growth of prostate cancer cells.
- Trial name
- NCT00002597
- Testing
- flutamide, Zoladex, Lupron
- Where
- 239 sites in United States, Canada
- Volunteers
- 2,028 people
- Sponsor
- Radiation Therapy Oncology Group
High Risk Prostate Cancer
PRospective Observational Study of STereotactic Body rAdiation Therapy With Androgen Deprivation Therapy for Organ-confined High-risk Prostate Cancer: the PROSTAR Trial
Prostate Cancer (PCa) is the second most common malignancy and the 5th common cause of cancer-related mortality in men worldwide.
- Trial name
- PROSTAR (NCT06949254)
- Where
- 3 sites in Italy
- Volunteers
- 49 people
- Sponsor
- Istituto Clinico Humanitas
Salivary Gland Cancer, Salivary Duct Carcinoma
PSMA-PET Imaging Before and After ADT in Advanced SDC Patients
Explorative study, which evaluates the effect of androgen deprivation therapy (ADT) on the PSMA ligand uptake on 68Ga-PSMA-PET/CT in salivary duct carcinoma patients.
- Trial name
- ADT-SCAN (NCT04214353)
- Testing
- 68Ga-PSMA-PET/CT, 18FDG-PET/CT
- Where
- Netherlands
- Volunteers
- 14 people
- Sponsor
- Radboud University Medical Center
Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma
PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer
This phase I trial studies the side effects and best dose of multitargeted tyrosine kinase inhibitor PLX3397 (PLX3397) when given together with radiation therapy and antihormone therapy in treating patients with prostate cancer…
- Conditions
- Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma
- Trial name
- NCT02472275
- Testing
- Antiandrogen Therapy, Laboratory Biomarker Analysis, Multitargeted Tyrosine Kinase Inhibitor PLX3397
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostate Cancer
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
The purpose of this study is to determine the benefit of enzalutamide versus placebo as assessed by overall survival and progression-free survival in patients with progressive metastatic prostate cancer who have failed androgen…
- Trial name
- PREVAIL (NCT01212991)
- Testing
- Enzalutamide
- Where
- 269 sites in United States, Australia and 20 more
- Volunteers
- 1,717 people
- Sponsor
- Pfizer
Intermediate Risk Prostate Cancer, High Risk Prostate Cancer
Androgen-responsive POSLUMA-guided Intra-prostatic Boost
This research study is for men with intermediate- or high-risk prostate cancer who are planning to receive hormone therapy and radiation treatment.
- Conditions
- Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Prostate Cancer
- Trial name
- ARPEGGIO (NCT07393867)
- Testing
- PSMA PET/CT, Androgen Deprivation Therapy (ADT) +/- bicalutamide, Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Martin T. King, MD, PhD
Prostate Cancer
Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer
The main objective of the trial to determine if the combination of apalutamide with 6 months of androgen deprivation therapy by LHRH agonists in patients with intermediate and limited high-risk, localized prostate cancer…
- Trial name
- ARN-509 (NCT03488810)
- Testing
- Radiation Therapy, Apalutamide, Luteinising Hormone Releasing Hormone analog agonist (LHRHa)
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
High-Risk Prostate Cancer
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
The purpose of this study is to learn about how an investigational drug intervention completed before doing prostate surgery (specifically, radical prostatectomy with lymph node dissection) may help in treatment of high risk…
- Trial name
- SNARE (NCT05593497)
- Testing
- Capivasertib, abiraterone acetate
- Where
- 9 sites in United States
- Volunteers
- 30 people
- Sponsor
- VA Office of Research and Development
Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
This phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with castration-sensitive prostate cancer that has spread to limited…
- Conditions
- Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Ductal Adenocarcinoma, Prostate Intraductal Carcinoma
- Trial name
- NCT05053152
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 245 sites in United States, Canada
- Volunteers
- 194 people
- Sponsor
- NRG Oncology
Prostate Cancer
Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases
The aim of the study is to investigate, the effect of radical prostatectomy with extended lymphadenectomy on cancer-specific survival, time to castration-resistance, time to progression and quality of life in patients with a…
- Trial name
- g-RAMPP (NCT02454543)
- Testing
- Radical prostatectomy, Best systemic therapy
- Where
- Germany
- Volunteers
- 452 people
- Sponsor
- Martini-Klinik am UKE GmbH
Prostate Cancer
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer
For this study, unfavorable intermediate risk prostate cancer patients will select whether they are to be treated with the standard of care (SOC) 6 months of Androgen Deprivation Therapy (ADT) in conjunction with stereotactic…
- Trial name
- NCT06397703
- Testing
- Leuprolide, Degarelix or Relugolix, Stereotactic body radiation therapy/radiosurgery (SBRT)
- Where
- United States
- Volunteers
- 392 people
- Sponsor
- NYU Langone Health
Prostate Cancer
Bone Health Observational Study
Prostate Cancer patients treated with LHRH agonists (e.g., goserelin) lose Bone Mineral Density (BMD). Using a prospective, observational study design, we propose that monitoring how physicians manage Cancer Treatment Induced…
- Trial name
- BHOS (NCT00632905)
- Where
- 40 sites in Canada
- Volunteers
- 599 people
- Sponsor
- CMX Research